Valeura Energy Inc.: Final Investment Decision on Wassana Field Redevelopment
Notified -
Globe Newswire14-05-2025, 14:57
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai 18-09-2024, 22:07